文献速递脑血管病神经重症与神经感染神经肌肉病

COVID-19的神经系统关联

Neurological associations of COVID-19.
PubMed 文献 · Lancet Neurol · 2020-07-02

该综述基于病例报告和队列研究,汇总了SARS-CoV-2感染者的神经系统表现。共描述901例患者,包括脑病93例、脑炎8例、吉兰-巴雷综合征19例、卒中96例,急性脑血管病占住院患者的2-6%。嗅觉丧失和味觉障碍常见,可在无其他症状时出现。需精确病例定义区分非特异性并发症与病毒直接或间接所致疾病。

要点

  • 脑病可见于COVID-19住院患者,武汉报道16/214(7%),法国ICU报道40/58(69%)。
  • 急性脑血管病是重要并发症,住院患者卒中比例为2-6%,常伴炎症性高凝状态。
  • 嗅觉丧失和味觉障碍常见,可孤立出现;脑炎和吉兰-巴雷综合征罕见但已有报道。

核心结论

  • SARS-CoV-2感染可伴随多种神经系统表现,包括脑病、脑炎、吉兰-巴雷综合征、嗅觉味觉障碍和急性脑血管病。
  • 需精确病例定义以区分重症非特异性并发症与病毒直接或间接所致神经系统疾病。

研究设计与样本

  • 综述汇总病例报告和病例系列,共描述901例患者的神经系统表现。
  • 引用队列研究数据:武汉214例住院患者中16例(7%)出现脑病;法国58例ICU患者中40例(69%)出现脑病。

主要发现

  • 脑病共报告93例,包括武汉住院患者的16/214(7%)和法国ICU患者的40/58(69%)。
  • 脑炎报告8例,吉兰-巴雷综合征报告19例,部分患者脑脊液检测到SARS-CoV-2。
  • 卒中报告96例,住院患者卒中比例为2-6%,常伴C反应蛋白、D-二聚体和铁蛋白升高。
  • 嗅觉丧失和味觉障碍常见,可在无其他临床特征时出现。

关键数值与推荐

  • 住院COVID-19患者卒中比例为2-6%。
  • 武汉住院患者脑病比例为16/214(7%),法国ICU患者脑病比例为40/58(69%)。
  • 脑炎8例,吉兰-巴雷综合征19例,卒中96例。

临床怎么用

  • 对COVID-19患者应警惕脑病、卒中、吉兰-巴雷综合征及嗅觉味觉障碍等神经系统表现。
  • 在呼吸道感染轻微或无症状的患者中识别SARS-CoV-2相关神经系统疾病可能具有挑战性,尤其当原发感染发生在数周前。
  • 需使用精确病例定义区分重症非特异性并发症(如缺氧性脑病和危重症神经病)与病毒直接或间接所致疾病。

局限性

  • 许多病例报告和系列细节不足,反映研究此类患者的挑战。
  • 神经系统疾病在感染中的比例可能仍较小,但患者可能遗留严重神经后遗症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is of a scale not seen since the 1918 influenza pandemic. Although the predominant clinical presentation is with respiratory disease, neurological manifestations are being recognised increasingly. On the basis of knowledge of other coronaviruses, especially those that caused the severe acute respiratory syndrome and Middle East respiratory syndrome epidemics, cases of CNS and peripheral nervous system disease caused by SARS-CoV-2 might be expected to be rare. RECENT DEVELOPMENTS: A growing number of case reports and series describe a wide array of neurological manifestations in 901 patients, but many have insufficient detail, reflecting the challenge of studying such patients. Encephalopathy has been reported for 93 patients in total, including 16 (7%) of 214 hospitalised patients with COVID-19 in Wuhan, China, and 40 (69%) of 58 patients in intensive care with COVID-19 in France. Encephalitis has been described in eight patients to date, and Guillain-Barré syndrome in 19 patients. SARS-CoV-2 has been detected in the CSF of some patients. Anosmia and ageusia are common, and can occur in the absence of other clinical features. Unexpectedly, acute cerebrovascular disease is also emerging as an important complication, with cohort studies reporting stroke in 2-6% of patients hospitalised with COVID-19. So far, 96 patients with stroke have been described, who frequently had vascular events in the context of a pro-inflammatory hypercoagulable state with elevated C-reactive protein, D-dimer, and ferritin. WHERE NEXT?: Careful clinical, diagnostic, and epidemiological studies are needed to help define the manifestations and burden of neurological disease caused by SARS-CoV-2. Precise case definitions must be used to distinguish non-specific complications of severe disease (eg, hypoxic encephalopathy and critical care neuropathy) from those caused directly or indirectly by the virus, including infectious, para-infectious, and post-infectious encephalitis, hypercoagulable states leading to stroke, and acute neuropathies such as Guillain-Barré syndrome. Recognition of neurological disease associated with SARS-CoV-2 in patients whose respiratory infection is mild or asymptomatic might prove challenging, especially if the primary COVID-19 illness occurred weeks earlier. The proportion of infections leading to neurological disease will probably remain small. However, these patients might be left with severe neurological sequelae. With so many people infected, the overall number of neurological patients, and their associated health burden and social and economic costs might be large. Health-care planners and policy makers must prepare for this eventuality, while the many ongoing studies investigating neurological associations increase our knowledge base.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020. PMID: 32622375. doi:10.1016/S1474-4422(20)30221-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。